Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

News Daily News

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Yael L. Maxwell

May 16, 2019

News Daily News

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

L.A. McKeown

March 21, 2019

News Daily News

Signal of Aortic Stenosis Risk With Celecoxib

Michael O'Riordan

March 05, 2019

News Daily News

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

Todd Neale

March 04, 2019

News Daily News

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Michael O'Riordan

February 26, 2019

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

News Daily News

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Caitlin E. Cox

January 24, 2019

Advertisement

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

Signal of Aortic Stenosis Risk With Celecoxib

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content